Stilbene-pyridazinone hybrids: design, synthesis and in vitro antiplatelet activity screening

Abstract

A series of stilbene analogues, in which a phenyl ring was replaced by the pyridazin-3(2H)-one nucleus, was designed and synthesized to be explored as platelet aggregation inhibitors. The proposed stilbene-pyridazinone hybrids were successfully obtained from simple starting materials and by Wittig’s reaction. Most of the target compounds displayed improvedin vitroactivity in comparison with the standard drug, resveratrol, highlighting as the most potent the analogues10dand10e, with inhibition percentages of 94.15 % at 100 µM and 100 % at 50 µM, respectively.The pharmacokinetic and toxicity (ADME/T) properties of the novel hybrids were also estimated with the SwissADME and ProTox-II web servers.